Lexicon Pharmaceuticals Inc (LXRX)

15.61
NASDAQ : Health Care
Prev Close 15.61
Day Low/High 15.46 / 15.74
52 Wk Low/High 11.52 / 19.62
Avg Volume 919.70K
Exchange NASDAQ
Shares Outstanding 104.32M
Market Cap 1.63B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017

Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017

Conference Call and Webcast to Follow

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

Here are some names that have caught our eye.

Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes

Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes

New Oral, Small Molecule Investigational Drug Is Designed to Inhibit SGLT1 in the GI Tract with Minimal Systemic Absorption

First Week of LXRX February 2017 Options Trading

First Week of LXRX February 2017 Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.

Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Conference call and webcast December 21, 2016 at 8:30 a.m. Eastern Time

Notable Friday Option Activity: LXRX, WTW, XBIT

Notable Friday Option Activity: LXRX, WTW, XBIT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lexicon Pharmaceuticals, Inc. , where a total volume of 6,103 contracts has been traded thus far today, a contract volume which is representative of approximately 610,300 underlying shares (given that every 1 contract represents 100 underlying shares).

Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRF

Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRF

Study Conducted in Young Adults with Type 1 Diabetes and High Baseline A1C

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AYR, CRCM, TG Downgrades: ADPT, AMZN, ANGI, ARNC, BKD, BWXT, CAJ, CALX, CSGP, EMR, HZO, LXRX, MNK, MYGN, NTRA, PBI, TCO, TRI Initiations: PFGC Read on to get TheStreet Quant Ratings' detailed report:

Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology

Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology

Results from Pivotal Phase 3 Clinical Study of Telotristat Ethyl Show Clinical Benefit in Patients with Carcinoid Syndrome

Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes

Results Support Phase 3 Dose Selection and Differentiated Dual SGLT1/SGLT2 Mechanism

Lexicon To Report Third Quarter 2016 Financial Results On November 1, 2016

Lexicon To Report Third Quarter 2016 Financial Results On November 1, 2016

Conference Call and Webcast to Follow

Short Interest In Lexicon Pharmaceuticals Moves 16% Higher

Short Interest In Lexicon Pharmaceuticals Moves 16% Higher

The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 2,011,299 share increase in total short interest for Lexicon Pharmaceuticals, Inc. , to 14,608,790, an increase of 15.97% since 09/15/2016.

Telecast Data Presented At The 2016 North American Neuroendocrine Tumor Society Annual Symposium

Telecast Data Presented At The 2016 North American Neuroendocrine Tumor Society Annual Symposium

First Presentation at a Scientific Meeting of Data from Companion Phase 3 Trial Designed to Assess Safety of Telotristat Ethyl for Carcinoid Syndrome

FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome

FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome

PDUFA Goal Date Extended to February 28, 2017

Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

First Successful Phase 3 Trial of an Oral Anti-diabetic for Type 1 Diabetes